Sun MH, Yi WD, Shen L, Zhou L, Lu JX. Transcatheter arterial infusion chemotherapy and embolization for primary lacrimal sac squamous cell carcinoma: A case report. World J Clin Cases 2022; 10(21): 7467-7473 [PMID: 36157994 DOI: 10.12998/wjcc.v10.i21.7467]
Corresponding Author of This Article
Jian-Xun Lu, MD, Assistant Professor, Department of Oncology, The First People's Hospital of Nanning, No. 89 Qixing Road, Nanning 530022, Guangxi Zhuang Autonomous Region, China. lujianxun1970@sina.com
Research Domain of This Article
Oncology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jul 26, 2022; 10(21): 7467-7473 Published online Jul 26, 2022. doi: 10.12998/wjcc.v10.i21.7467
Transcatheter arterial infusion chemotherapy and embolization for primary lacrimal sac squamous cell carcinoma: A case report
Ming-Hui Sun, Wei-Dong Yi, Ling Shen, Lu Zhou, Jian-Xun Lu
Ming-Hui Sun, Wei-Dong Yi, Ling Shen, Lu Zhou, Jian-Xun Lu, Department of Oncology, The First People's Hospital of Nanning, Nanning 530022, Guangxi Zhuang Autonomous Region, China
Author contributions: Sun MH was a major contributor in writing the manuscript; Lu JX and Yi WD analyzed and interpreted the patient data for transcatheter arterial infusion chemotherapy and embolization for primary lacrimal sac squamous cell carcinoma; Zhou L and Shen L presented information and contributed to editing and revision of the article; all authors approved submission of the manuscript.
Supported bythe Self-funded Project of the Health Committee of Guangxi Zhuang Autonomous Region, No. z20190848.
Informed consent statement: Written consent to publish information was obtained from the patient.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jian-Xun Lu, MD, Assistant Professor, Department of Oncology, The First People's Hospital of Nanning, No. 89 Qixing Road, Nanning 530022, Guangxi Zhuang Autonomous Region, China. lujianxun1970@sina.com
Received: November 24, 2021 Peer-review started: November 24, 2021 First decision: April 13, 2022 Revised: April 28, 2022 Accepted: June 3, 2022 Article in press: June 3, 2022 Published online: July 26, 2022 Processing time: 229 Days and 4.5 Hours
Abstract
BACKGROUND
Although tumors of the lacrimal sac are rare, they represent a potentially life-threatening situation that can easily be overlooked since patients present with features consistent with chronic dacryocystitis. Lacrimal sac squamous cell carcinoma is the most common lacrimal sac malignancy, but no definitive treatment is currently available.
CASE SUMMARY
We describe a 34-year-old unmarried male who presented with a red and swollen right lower eyelid, which gradually developed into a mass of the lower eyelid that obstructed vision in his right eye. He was treated with transcatheter arterial infusion chemotherapy and interventional embolization based on the tumor characteristics, and we also administered intensity-modulated radiotherapy and targeted therapy after tumor shrinkage. The tumor treatment demonstrated good efficacy, and the patient’s condition was stable after 10 mo of follow-up.
CONCLUSION
To our knowledge, this is the first report of lacrimal sac squamous cell carcinoma treated with transcatheter arterial infusion chemotherapy and interventional embolization, which might expand clinical treatment options for lacrimal sac carcinoma.
Core Tip: Tumors of the lacrimal sac are extremely rare but are potentially devastating lesions that lack an effective remedy. We present a case of lacrimal sac squamous cell carcinoma that was treated with transcatheter arterial infusion chemotherapy and interventional embolization to provide a reference for the treatment of primary lacrimal sac tumors.
